mirtazapine has been researched along with Impairment, Light Touch Sensation in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, EH | 1 |
| Lee, IS | 1 |
| Chung, SK | 1 |
| Lee, SY | 1 |
| Kim, EJ | 1 |
| Hong, JP | 1 |
| Oh, KS | 1 |
| Woo, JM | 1 |
| Kim, S | 1 |
| Park, JE | 1 |
| Yu, BH | 1 |
1 trial available for mirtazapine and Impairment, Light Touch Sensation
| Article | Year |
|---|---|
Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc | 2009 |